Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0RZJIL
ADC Name	Tamrintamab pamozirine
Synonyms	SC 003; SC-003; SC003 Click to Show/Hide
Organization	AbbVie, Inc.; Stemcentrx, Inc.
Drug Status	Phase 1
Indication	In total 1 Indication(s) Ovarian cancer [ICD11:2C73] Phase 1
	3D MOL	2D MOL
Antibody Name	Tamrintamab		Antibody Info
Antigen Name	Dipeptidase 3 (DPEP3)		Antigen Info
Payload Name	SC-DR002		Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Puchem SID	381608747 , 472420778 , 476269495 , 476262899

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Partial Response (PR)	NCT02539719	Phase 1	A phase 1a/1b dose escalation and expansion study of SC-003 as a single-agent and in combination with ABBV-181 in subjects with platinum-resistant/ refractory ovarian cancer.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Partial Response (PR)	1.72%
Patients Enrolled	Female patients (age 18 years) with EOC if they had evidence of progressive disease during or within 6 months of receiving a platinum regimen.
Administration Dosage	1 of 6 dose levels (0.025-0.40 mg/kg) every 3 weeks (Q3W), utilizing a standard 3+3 design (dose-limiting toxicity [DLT] period: 21 days).
*Related Clinical Trial*
NCT Number	NCT02539719	Clinical Status	Phase 1
Clinical Description	A phase 1a/1b dose escalation and expansion study of SC-003 as a single-agent and in combination with ABBV-181 in subjects with platinum-resistant/ refractory ovarian cancer.
Primary Endpoint	The MTD for the Q3W schedule was 0.30 mg/kg and the SC-003 doses selected for the dose-expansion phase of the study were 0.30 mg/kg and 0.20 mg/kg.
Other Endpoint	ORR=5.17% (N=3/58), 3 patients achieved PR. All responses were observed at 0.20-0.30mg/kg. Responses were not durable, with only 1 PR confirmed on the follow-up 16-week scan.

References

Ref 1	Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 Sep;158(3):640-645.